Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Eli Lilly and Company(LLY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LLY
11/10/2026: LLY (5-star) is a STRONG-BUY. BUY for 18 days. Simulated Profits (13.94%). Updated daily EoD!
Eli Lilly and Company is a prominent global pharmaceutical firm recognized for its specialized medicines in metabolic, oncological, and neurological disorders. Its business is currently highlighted by the significant growth of its GLP-1 portfolio, which serves as a major revenue engine. The primary investment story centers on the company's ability to sustain high demand and capture market share in obesity and chronic disease treatments. Investors must balance this opportunity against high valuation premiums, regulatory pricing risks, and execution challenges regarding manufacturing capacity. The stock is best suited for growth-oriented investors and those monitoring large-cap pharmaceutical innovation, provided they are comfortable with the inherent volatility associated with high-growth medical franchises.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Lilly's strong product pipeline and market leadership in obesity drugs drive high growth expectations. |
| Momentum investor | Strong fit while signal remains positive | The stock has demonstrated strong price momentum driven by commercial success in its metabolic segment. |
| Value investor | Weak fit | High valuation multiples based on future earnings growth make it less attractive for traditional value investors. |
| Dividend investor | Mixed fit | While the company pays a dividend, the yield is modest, reflecting a focus on capital appreciation. |
| Low-risk investor | Mixed fit | Pharmaceutical sector volatility and high valuation premiums introduce risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | High expectations for new drug launches can cause sharp swings in share price based on clinical or earnings news. |
| Valuation risk | High | The stock trades at a premium valuation that requires flawless execution to justify current pricing. |
| Competition risk (Metabolic/Obesity) | Medium / high | Intense rivalry with Novo Nordisk and other developers of GLP-1 and non-GLP-1 weight-loss agents threatens future pricing and market share. |
| Business quality | Strong | Lilly possesses a high-quality portfolio with strong pricing power and significant barriers to entry. |
| Dividend income | Low | Investors should not rely on the stock for high current income, as the focus is on reinvestment. |
| Execution risk | Medium | The company faces significant logistical challenges in manufacturing and distributing its injectable obesity products to meet global demand. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 59.16% | Avg. Invested days 43 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 1.26T USD | Price to earnings Ratio 43.94 | 1Y Target Price 1453.4 |
Price to earnings Ratio 43.94 | 1Y Target Price 1453.4 | ||
Volume (30-day avg) 2.8M shares | Beta 0.39 | 52 Weeks Range 847.83 - 1453.00 | Updated Date 11/09/2026 |
52 Weeks Range 847.83 - 1453.00 | Updated Date 11/09/2026 | ||
Dividends yield (FY) 0.49% | Basic EPS (TTM) 32.13 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Human Pharmaceuticals | Includes sales of Mounjaro, Zepbound, Verzenio, Taltz, and other portfolio drugs. | The company makes money primarily by selling patented, high-value prescription drugs to healthcare providers and pharmacy networks. |
| Geography | Revenue distribution across the United States and international markets. | The US is the primary driver of revenue, though international markets remain important for long-term product adoption. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 5.38 | Actual 7.48 |
Profitability
Profit Margin 31.9% | Operating Margin (TTM) 53.66% |
Management Effectiveness
Return on Assets (TTM) 21.06% | Return on Equity (TTM) 86.02% |
Valuation
Trailing PE 43.94 | Forward PE 27.17 | Enterprise Value 1.25T | Price to Sales(TTM) 14.55 |
Enterprise Value 1.25T | Price to Sales(TTM) 14.55 | ||
Enterprise Value to Revenue 14.47 | Enterprise Value to EBITDA 26.9 | Shares Outstanding 890.75M | Shares Floating 888.35M |
Shares Outstanding 890.75M | Shares Floating 888.35M | ||
Percent Insiders 0.15 | Percent Institutions 85.54 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.